<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00006252</url>
  </required_header>
  <id_info>
    <org_study_id>CALGB-109901</org_study_id>
    <secondary_id>U10CA031946</secondary_id>
    <secondary_id>CALGB-109901</secondary_id>
    <secondary_id>CDR0000068185</secondary_id>
    <nct_id>NCT00006252</nct_id>
  </id_info>
  <brief_title>Fludarabine and Cyclophosphamide Followed by Peripheral Stem Cell Transplant in Treating Patients With Leukemia or Lymphoma</brief_title>
  <official_title>Minimal Ablation and Cellular Immune Therapy of Chronic Lymphocytic Leukemia, Prolymphocytic Leukemia, Low-Grade Non-Hodgkin's Lymphoma, and Mantle Cell Lymphoma With Allogeneic Donor Stem Cells</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cancer and Leukemia Group B</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Alliance for Clinical Trials in Oncology</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Giving chemotherapy drugs, such as fludarabine and cyclophosphamide, before a&#xD;
      donor peripheral blood stem cell transplant helps stop the growth of cancer cells. It also&#xD;
      helps stop the patient's immune system from rejecting the donor's stem cells. When the&#xD;
      healthy stem cells from a donor are infused into the patient they may help the patient's bone&#xD;
      marrow make stem cells, red blood cells, white blood cells, and platelets.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well fludarabine and cyclophosphamide followed&#xD;
      by peripheral stem cell transplant works in treating patients with leukemia or lymphoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the feasibility of fludarabine and cyclophosphamide followed by allogeneic&#xD;
           peripheral blood stem cell transplantation, in terms of 6-month treatment-related&#xD;
           mortality, in patients with chronic lymphocytic leukemia, prolymphocytic leukemia,&#xD;
           low-grade non-Hodgkin's lymphoma, or mantle cell lymphoma.&#xD;
&#xD;
        -  Determine the 6-month and 12-month probabilities of response in patients treated with&#xD;
           this regimen.&#xD;
&#xD;
        -  Determine the time to disease progression in patients responding to this regimen.&#xD;
&#xD;
        -  Determine the percentage of donor chimerism achieved in patients treated with this&#xD;
           regimen.&#xD;
&#xD;
        -  Determine the risk of acute and chronic graft-versus-host disease in patients treated&#xD;
           with this regimen.&#xD;
&#xD;
        -  Determine the toxic effects of this regimen in these patients.&#xD;
&#xD;
        -  Determine the overall survival and disease-free survival of patients treated with this&#xD;
           regimen.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
      Patients receive fludarabine IV over 30 minutes on days -7 to -3 and cyclophosphamide IV over&#xD;
      1 to 2 hours on days -5 to -3. Patients undergo allogeneic peripheral blood stem cell&#xD;
      transplantation on days 0-1. Patients then receive filgrastim (G-CSF) subcutaneously daily&#xD;
      beginning on day 5 and continuing until blood counts recover.&#xD;
&#xD;
      Patients with no signs of active graft-versus host disease and stable or progressive disease&#xD;
      receive donor lymphocytes IV over 2 hours beginning after day 120. Patients may receive a&#xD;
      total of 3 infusions at least 8 weeks apart if disease remains stable or progressive.&#xD;
&#xD;
      Patients are followed every 3 months for 2 years and then every 6 months for 5 years.&#xD;
&#xD;
      PROJECTED ACCRUAL: A maximum of 45 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2001</start_date>
  <completion_date type="Actual">October 2011</completion_date>
  <primary_completion_date type="Actual">January 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment-related mortality within the first 6 months post-transplant</measure>
    <time_frame>6 months post chemo initiation</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response</measure>
    <time_frame>6 months &amp; 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients achieving complete donor chimerism or mixed donor chimerism</measure>
    <time_frame>90 days post transplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
    <time_frame>5 years post study entry</time_frame>
    <description>Disease free and overall survival will be assessed</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">47</enrollment>
  <condition>Leukemia</condition>
  <condition>Lymphoma</condition>
  <arm_group>
    <arm_group_label>Allogeneic Stem Cell Tx</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>minimal ablation and cellular immune therapy with allogeneic donor stem cell therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fludarabine phosphate</intervention_name>
    <description>30 mg/sq m/day IV infusion for 5 days (Days -7 thru -3)</description>
    <arm_group_label>Allogeneic Stem Cell Tx</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>1 g/sq m/day IV infusion x 3 days (Days -5 thru -3)</description>
    <arm_group_label>Allogeneic Stem Cell Tx</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PBSC</intervention_name>
    <description>2-8,000,000/kg CD34+ cells via infusion on Day 0</description>
    <arm_group_label>Allogeneic Stem Cell Tx</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>G-CSF</intervention_name>
    <description>5 ug/kg/day subQ injection until ANC &gt; 1000/uL for 3 days beginning Day 5</description>
    <arm_group_label>Allogeneic Stem Cell Tx</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Donor lymphocytes</intervention_name>
    <description>10,000,000 CD3+ cells/kg via infusion</description>
    <arm_group_label>Allogeneic Stem Cell Tx</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  One of the following histologically confirmed diagnoses:&#xD;
&#xD;
               -  Chronic lymphocytic leukemia&#xD;
&#xD;
                    -  Absolute lymphocytosis greater than 5,000/mm^3&#xD;
&#xD;
                    -  Morphologically mature lymphocytes with less than 55% prolymphocytes&#xD;
&#xD;
                    -  Lymphocyte phenotypic expression of CD19 and CD5&#xD;
&#xD;
                    -  Failed at least 1 prior regimen&#xD;
&#xD;
                         -  Progressive lymphocytosis with more than 50% increase in peripheral&#xD;
                            lymphocytosis or a progressive lymph node or spleen enlargement (at&#xD;
                            least 25% enlargement or the appearance of new lymph nodes) that&#xD;
                            persists for at least 4 weeks despite concurrent or prior drug&#xD;
                            treatment OR&#xD;
&#xD;
                    -  At least 1 of the following high-risk factors and not in first complete&#xD;
                       remission&#xD;
&#xD;
        = 17p deletion = 11q deletion&#xD;
&#xD;
          -  Unmutated VH gene status&#xD;
&#xD;
          -  p53 mutations&#xD;
&#xD;
               -  Prolymphocytic leukemia (PLL)&#xD;
&#xD;
                    -  Absolute lymphocytosis greater than 5,000/mm^3&#xD;
&#xD;
                    -  Morphologically mature lymphocytes with more than 55% prolymphocytes&#xD;
&#xD;
               -  Low-grade non-Hodgkin's lymphoma&#xD;
&#xD;
                    -  Small lymphocytic lymphoma&#xD;
&#xD;
                    -  Follicular center lymphoma (grade I or II)&#xD;
&#xD;
                    -  Diffuse (predominately small cell type)&#xD;
&#xD;
                    -  Marginal zone, B-cell lymphoma&#xD;
&#xD;
                    -  No transformed lymphoma&#xD;
&#xD;
                    -  Failure of at least 1 prior regimen OR&#xD;
&#xD;
                    -  At least 3 of the following risk factors:&#xD;
&#xD;
          -  Over 60 years of age&#xD;
&#xD;
          -  Performance status greater than 1&#xD;
&#xD;
          -  LDH greater than normal&#xD;
&#xD;
          -  More than 1 site of extranodal disease&#xD;
&#xD;
          -  Disease stage III or IV&#xD;
&#xD;
               -  Mantle cell lymphoma&#xD;
&#xD;
                    -  Any stage&#xD;
&#xD;
                    -  Ineligible for protocol CALGB-59908&#xD;
&#xD;
                    -  At least 1 prior treatment regimen&#xD;
&#xD;
                    -  At least 1 of the following:&#xD;
&#xD;
          -  Immunophenotypic expression of CD5 and CD19 and absence of CD23&#xD;
&#xD;
          -  Cytogenetic analysis with presence of t(11;14)&#xD;
&#xD;
          -  Overexpression of cyclin D1&#xD;
&#xD;
          -  Rearrangement of BCL1 gene&#xD;
&#xD;
               -  Responsive or stable disease to most recent prior therapy&#xD;
&#xD;
                    -  Prior therapy for PLL not required&#xD;
&#xD;
               -  Must have HLA identical sibling (6/6) donor by serologic typing (A, B, DR)&#xD;
&#xD;
                    -  No syngeneic donors&#xD;
&#xD;
                    -  No age restriction NOTE: A new classification scheme for adult non-Hodgkin's&#xD;
                       lymphoma has been adopted by PDQ. The terminology of &quot;indolent&quot; or&#xD;
                       &quot;aggressive&quot; lymphoma will replace the former terminology of &quot;low&quot;,&#xD;
                       &quot;intermediate&quot;, or &quot;high&quot; grade lymphoma. However, this protocol uses the&#xD;
                       former terminology.&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  Under 70&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Granulocyte count at least 500/mm^3*&#xD;
&#xD;
          -  Platelet count at least 50,000/mm^3* NOTE: *Unless attributable to disease&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin no greater than 3 times upper limit of normal (ULN)*&#xD;
&#xD;
          -  AST no greater than 3 times ULN* NOTE: *Unless attributable to disease&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine clearance at least 40 mL/min, unless attributable to disease&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  LVEF at least 30% by MUGA&#xD;
&#xD;
        Pulmonary:&#xD;
&#xD;
          -  DLCO greater than 40%&#xD;
&#xD;
          -  No symptomatic pulmonary disease&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  No uncontrolled diabetes mellitus&#xD;
&#xD;
          -  No active serious infection&#xD;
&#xD;
          -  No known hypersensitivity to E. coli-derived products&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  No prior autologous transplantation&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  At least 4 weeks since prior chemotherapy&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  At least 4 weeks since prior radiotherapy&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  At least 4 weeks since prior surgery&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>69 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Shea, MD</last_name>
    <role>Study Chair</role>
    <affiliation>UNC Lineberger Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rebecca and John Moores UCSD Cancer Center</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093-0658</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Veterans Affairs Medical Center - San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92161</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCSF Comprehensive Cancer Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beebe Medical Center</name>
      <address>
        <city>Lewes</city>
        <state>Delaware</state>
        <zip>19958</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Christiana Care Health Services</name>
      <address>
        <city>Newark</city>
        <state>Delaware</state>
        <zip>19713</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Francis Hospital</name>
      <address>
        <city>Wilmington</city>
        <state>Delaware</state>
        <zip>19805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Holden Comprehensive Cancer Center at University of Iowa</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Union Hospital Cancer Center at Union Hospital</name>
      <address>
        <city>Elkton MD</city>
        <state>Maryland</state>
        <zip>21921</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMASS Memorial Cancer Center - University Campus</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01655</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Institute of New Jersey at the Cooper University Hospital - Voorhees</name>
      <address>
        <city>Voorhees</city>
        <state>New Jersey</state>
        <zip>08043</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263-0001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Elmhurst Hospital Center</name>
      <address>
        <city>Elmhurst</city>
        <state>New York</state>
        <zip>11373</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queens Cancer Center of Queens Hospital</name>
      <address>
        <city>Jamaica</city>
        <state>New York</state>
        <zip>11432</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599-7295</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Forest University Comprehensive Cancer Center</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157-1096</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210-1240</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Western Pennsylvania Cancer Institute at Western Pennsylvania Hospital</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224-1791</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massey Cancer Center at Virginia Commonwealth University</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298-0037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Shea T, Johnson J, Westervelt P, Farag S, McCarty J, Bashey A, Isola L, Baxter-Lowe LA, Kelly M, Owzar K, Linker C; Cancer and Leukemia Group B. Reduced-intensity allogeneic transplantation provides high event-free and overall survival in patients with advanced indolent B cell malignancies: CALGB 109901. Biol Blood Marrow Transplant. 2011 Sep;17(9):1395-403. doi: 10.1016/j.bbmt.2011.01.016. Epub 2011 Feb 3.</citation>
    <PMID>21296675</PMID>
  </results_reference>
  <verification_date>July 2016</verification_date>
  <study_first_submitted>September 11, 2000</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>July 15, 2016</last_update_submitted>
  <last_update_submitted_qc>July 15, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 18, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>refractory chronic lymphocytic leukemia</keyword>
  <keyword>stage I grade 1 follicular lymphoma</keyword>
  <keyword>stage I grade 2 follicular lymphoma</keyword>
  <keyword>stage I adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>stage III grade 1 follicular lymphoma</keyword>
  <keyword>stage III grade 2 follicular lymphoma</keyword>
  <keyword>stage III adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>stage IV grade 1 follicular lymphoma</keyword>
  <keyword>stage IV grade 2 follicular lymphoma</keyword>
  <keyword>stage IV adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>recurrent grade 1 follicular lymphoma</keyword>
  <keyword>recurrent grade 2 follicular lymphoma</keyword>
  <keyword>recurrent adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>prolymphocytic leukemia</keyword>
  <keyword>stage I mantle cell lymphoma</keyword>
  <keyword>contiguous stage II grade 1 follicular lymphoma</keyword>
  <keyword>contiguous stage II grade 2 follicular lymphoma</keyword>
  <keyword>contiguous stage II adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>contiguous stage II mantle cell lymphoma</keyword>
  <keyword>noncontiguous stage II grade 1 follicular lymphoma</keyword>
  <keyword>noncontiguous stage II grade 2 follicular lymphoma</keyword>
  <keyword>noncontiguous stage II adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>noncontiguous stage II mantle cell lymphoma</keyword>
  <keyword>stage III mantle cell lymphoma</keyword>
  <keyword>stage IV mantle cell lymphoma</keyword>
  <keyword>recurrent mantle cell lymphoma</keyword>
  <keyword>contiguous stage II small lymphocytic lymphoma</keyword>
  <keyword>contiguous stage II marginal zone lymphoma</keyword>
  <keyword>noncontiguous stage II small lymphocytic lymphoma</keyword>
  <keyword>noncontiguous stage II marginal zone lymphoma</keyword>
  <keyword>extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue</keyword>
  <keyword>nodal marginal zone B-cell lymphoma</keyword>
  <keyword>splenic marginal zone lymphoma</keyword>
  <keyword>recurrent marginal zone lymphoma</keyword>
  <keyword>recurrent small lymphocytic lymphoma</keyword>
  <keyword>stage I marginal zone lymphoma</keyword>
  <keyword>stage I small lymphocytic lymphoma</keyword>
  <keyword>stage III small lymphocytic lymphoma</keyword>
  <keyword>stage III marginal zone lymphoma</keyword>
  <keyword>stage IV small lymphocytic lymphoma</keyword>
  <keyword>stage IV marginal zone lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

